Diabetic Macular Edema Market, Epidemiology, Therapies, Companies Working in the Market | Companies – Ocuphire Pharma, Oxurion, YD Life Science, Novartis

May 15 18:13 2023
Diabetic Macular Edema Market, Epidemiology, Therapies, Companies Working in the Market | Companies - Ocuphire Pharma, Oxurion, YD Life Science, Novartis
Diabetic Macular Edema Market
DelveInsight’s “Diabetic Macular Edema (DME) – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Diabetic Macular Edema (DME), historical and forecasted epidemiology as well as the Diabetic Macular Edema (DME) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Diabetic Macular Edema (DME) is an accumulation of fluid in the macula part of the retina which arises as a consequence of failure of the blood-retinal barrier (BRB) due to leaking blood vessels. It is the leading cause of major vision loss in diabetic persons.  In order to develop DME, one must first have diabetic retinopathy (DR; damaged the blood vessels in the retina) that happen to people with diabetes. When DR is left untreated, these blood vessels begin to build up pressure in the eye and leak fluid, causing DME.

DelveInsight’s “Diabetic Macular Edema (DME) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the Diabetic Macular Edema (DME), historical and forecasted epidemiology as well as the Diabetic Macular Edema (DME) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market

Diabetic Macular Edema (DME) Disease Overview

There are two forms of DME:

  • Focal DME
  • Diffuse DME

Some common risk factors include those who have had diabetes for an extended amount of time, severe hypertension (high blood pressure), fluid retention, hypoalbuminemia (low levels of protein in body fluids), hyperlipidemia (high levels of fats in the blood).

Common symptoms of DME are:

  • Blurry vision
  • Floaters
  • Double vision
  • Blindness (if it goes untreated)

Focal DME occurs because of abnormalities in the blood vessels in the eye while diffuse DME occurs because of widening/swelling retinal capillaries (very thin blood vessels).

The DelveInsight Diabetic Macular Edema (DME) market report gives a thorough understanding of the Diabetic Macular Edema (DME) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Diabetic Macular Edema (DME) Treatment  

The treatment for DME involves rigorous glycemic control, macular laser treatment, intravitreal pharmacotherapy, especially with anti-VEGF, and surgical treatment. The treatments for focal and diffuse DME differ, but they both involve laser procedures. Most doctors use focal laser treatment to treat focal DME and grid laser treatment to treat diffuse DME. The goal of both kinds of procedures is to stop the leakage in the macula.

Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market

Diabetic Macular Edema (DME) Epidemiology Insights

Diabetic macular edema is a leading cause of vision loss among working-age adults in the U.S. Roughly 8% of the U.S. population is diabetic, and about 28% of those diabetics have eye trouble because of it. 

Diabetic Macular Edema (DME) Market Outlook

VEGF is a potent vasopermeability factor that has been targeted extensively in DME. The VEGF levels are significantly elevated in vitreous of DME patients when compared with nondiabetic eyes. Thus, the current therapies for DME involves the use of anti-VEGFs. Anti-VEGF treatment requires repeated intravitreous injections to maintain the therapeutic effect.

Other than these, steroid injections suppress pro-inflammatory chemokines, and inhibit leukostasis and phosphorylation of cell-junction proteins. Sustained release corticosteroids were developed in effort to decrease the number of injections a patient with DME requires.

According to DelveInsight, Diabetic Macular Edema market in 7MM is expected to change in the study period 2019-2032.

“As per a study, the costs for patients with DME were $28,606 compared with $16,363 for patients with diabetes mellitus (DM) but not DME.” 

Diabetic Macular Edema Companies:

• Adverum Biotechnologies

• Graybug Vision

• Roche

• Novartis

• KalVista Pharmaceuticals

• Ocuphire Pharma

• Oxurion

• YD Life Science

• Novartis

• Allergan (AbbVie)/Molecular Partners

• Allergo Opthalmics/ Bausch Health

• Kodiak Sciences

• Clearside Biomedical

Table of Contents:

1. Key Insights

2. Executive Summary of Diabetic Macular Edema (DME)

3. Competitive Intelligence Analysis for Diabetic Macular Edema (DME)

4. Diabetic Macular Edema (DME): Market Overview at a Glance

5. Diabetic Macular Edema (DME): Disease Background and Overview

6. Patient Journey

7. Diabetic Macular Edema (DME) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Diabetic Macular Edema (DME) Unmet Needs

10. Key Endpoints of Diabetic Macular Edema (DME) Treatment

11. Diabetic Macular Edema (DME) Marketed Products

12. Diabetic Macular Edema (DME) Emerging Therapies

13. Diabetic Macular Edema (DME): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Diabetic Macular Edema (DME)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/